CEO SUMMARY: In a partnership with Walgreens pharmacies, Theranos Inc. announced that it will run clinical lab tests on “micro-samples” and collect these blood samples without venipuncture. Even as Theranos touts the patient-friendly benefits of its proprietary diagnostic technology, it has provided no information about the science that supports this testing and the clinical validations
Theranos Won’t Discuss Disruptive Lab Technology
By Joseph Burns, from the Volume XX No. 13 - September 30, 2013 issue